RARRES2 and cancer: One of the proposed oncogenic mechanisms of TNFRSF11B is counteracting the anti-tumoral activity of TRAIL [87]; although its in vitro effects on cancer cell lines have to be further investigated, the present data suggest that the observed down-regulation of TNFRSF11B could possibly contribute to the observed effects of chemerin on OVCAR-3 cells.